Use of toxicological information in drug design

Journal of Molecular Graphics and Modelling

Volumn 18, Issue 6, 2000, Pages 605-615

  Matthews, E J ^a   Benz, R D ^a   Contrera, J F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; MOLECULAR STRUCTURE; TOXICITY;

SCIENTIFIC INFORMATION; STRUCTURE ACTIVITY RELATIONSHIPS (SAR);

MOLECULAR GRAPHICS;

COMPUTER PROGRAM; DATA ANALYSIS; DATA BASE; DRUG DESIGN; FOOD AND DRUG ADMINISTRATION; INFORMATION PROCESSING; INFORMATION SERVICE; INFORMATION SYSTEM; INTERNET; MOLECULAR MODEL; PRIORITY JOURNAL; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; TOXICOLOGY;

EID: 0034463184     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1093-3263(00)00119-4     Document Type: Short Survey

References (21)

1. Commercial toxicology prediction systems: A regulatory perspective
2. Application of artificial intelligence and computer-based methods to predicting chemical toxicity
3. The practice of structure activity relationships (SAR) in toxicology
4. Structure activity relationship methods applied to chemical toxicity: Making better use of what we have
5. Recent advances in computational toxicology and regulatory applications
6. A systemic exposure-based alternative to the maximum tolerated dose for carcinogenicity studies of human therapeutics
7. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals
8. The new chemicals process at the Environmental Protection Agency: Structure-activity relationships for hazard identification and risk assessment
9. Regulatory application of computational toxicology, now and in the future
10. Use of FDA databases, informatics and computational toxicology to estimate potential toxicity
11. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software
12. Stratification of carcinogenicity bioassay results to reflect relative human hazard
13. Describing the validity of carcinogen screening tests
14. CASE-SAR analysis of polycyclic aromatic hydrocarbon carcinogenicity
15. Assessment of the No-Effect-Level (NOEL) of chemicals in humans using pharmaceutical clinical trial data and MULTICASE software
16. Predicting human oral bioavailability of a compound, development of a novel quantitative structure-bioavailability relationship
17. A tiered approach to threshold of regulation
18. Safety assessment of cosmetic ingredients and color additives, evaluation of a quantitative structure-toxicity relationship approach for predicting toxicity
19. Integrating the QSAR paradigm into the safety assessment of cosmetic ingredients and color additives
20. The Cosmetic Ingredient Review